Regeneron Receives FDA Approval for Pozelimab in CD55-Deficient Protein-Losing Enteropathy

Regeneron today announced that the FDA has approved Veopoz (pozelimab-bbfg) for the treatment of adults and pediatric patients one year of age and older with CD55-deficient protein-losing enteropathy (CHAPLE disease). This marks the first approved treatment for CHAPLE disease.